Fatty Liver Disease - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 60 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Fatty Liver Disease - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Fatty Liver Disease - Pipeline Review, H2 2014', provides an overview of the Fatty Liver Disease's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Fatty Liver Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fatty Liver Disease and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Fatty Liver Disease
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Fatty Liver Disease and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Fatty Liver Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Fatty Liver Disease pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Fatty Liver Disease
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Fatty Liver Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Fatty Liver Disease Overview 7
Therapeutics Development 8
Pipeline Products for Fatty Liver Disease - Overview 8
Pipeline Products for Fatty Liver Disease - Comparative Analysis 9
Fatty Liver Disease - Therapeutics under Development by Companies 10
Fatty Liver Disease - Therapeutics under Investigation by Universities/Institutes 12
Fatty Liver Disease - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Fatty Liver Disease - Products under Development by Companies 15
Fatty Liver Disease - Products under Investigation by Universities/Institutes 16
Fatty Liver Disease - Companies Involved in Therapeutics Development 17
GW Pharmaceuticals plc 17
Protalix BioTherapeutics, Inc. 18
Genovate Biotechnology Co., LTD. 19
Huons Co., Ltd. 20
ChemoCentryx, Inc. 21
ACROVIS biostructures GmbH 22
Generon (Shanghai) Corporation Ltd. 23
Fatty Liver Disease - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 28
Assessment by Route of Administration 31
Assessment by Molecule Type 32
Drug Profiles 34
GWP-42003-P - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
etanercept biosimilar - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
F-652 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
CCX-872 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecule to Inhibit Them1 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
SR-9238 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
cSN-50 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
CSN-501 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
PCBB-7 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
HU-002 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
E06-ScFV - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
ACR-488 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Small Molecule to Inhibit IKK and TBK1 for Cardiovascular, Gastrointestinal and Metabolic Disorders - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Fatty Liver Disease - Recent Pipeline Updates 48
Fatty Liver Disease - Dormant Projects 50
Fatty Liver Disease - Product Development Milestones 51
Featured News & Press Releases 51
Jul 30, 2014: Galectin Therapeutics Issues Statement on GR-MD-02 Development Program 51
Jul 25, 2014: Galectin Therapeutics to Host Webcast to Discuss Findings From Cohort 2 of Phase 1 Clinical Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis 52
Jul 22, 2014: Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders 53
Mar 25, 2014: Galectin Therapeutics to Announce Results From First Cohort of Phase 1 Clinical Trial in Fatty Liver Disease 54
Mar 03, 2014: Conatus Pharmaceuticals Extends Liver Disease Reach With Phase 2 NAFLD/NASH Trial 55
Feb 26, 2014: Galectin Therapeutics Secures U.S. Patent for its Proprietary Galectin Inhibitor GR-MD-02 in Fatty Liver Disease 55
Jan 08, 2014: Galectin Therapeutics Reports on Key 2013 Scientific, Development and Regulatory Milestones, Highlights Corporate and Financial Activity 56
Sep 10, 2013: Galectin Therapeutics Receives US Patent for Potential Ground-Breaking Treatment for Fatty Liver Disease 56
Aug 12, 2013: Galectin Therapeutics Receives FDA Fast Track Designation for GR-MD-02 for Fatty Liver Disease With Advanced Fibrosis 57
Jul 24, 2013: Galectin Therapeutics Announces First Patient Dosed in Phase 1 Trial of GR-MD-02, a Potential First-in-Class Treatment for Fatty Liver Disease with Advanced Fibrosis 58
Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 60
Disclaimer 60

List of Tables
Number of Products under Development for Fatty Liver Disease, H2 2014 8
Number of Products under Development for Fatty Liver Disease - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 11
Number of Products under Investigation by Universities/Institutes, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Products under Investigation by Universities/Institutes, H2 2014 16
Fatty Liver Disease - Pipeline by GW Pharmaceuticals plc, H2 2014 17
Fatty Liver Disease - Pipeline by Protalix BioTherapeutics, Inc., H2 2014 18
Fatty Liver Disease - Pipeline by Genovate Biotechnology Co., LTD., H2 2014 19
Fatty Liver Disease - Pipeline by Huons Co., Ltd., H2 2014 20
Fatty Liver Disease - Pipeline by ChemoCentryx, Inc., H2 2014 21
Fatty Liver Disease - Pipeline by ACROVIS biostructures GmbH, H2 2014 22
Fatty Liver Disease - Pipeline by Generon (Shanghai) Corporation Ltd., H2 2014 23
Assessment by Monotherapy Products, H2 2014 24
Number of Products by Stage and Target, H2 2014 27
Number of Products by Stage and Mechanism of Action, H2 2014 30
Number of Products by Stage and Route of Administration, H2 2014 31
Number of Products by Stage and Molecule Type, H2 2014 33
Fatty Liver Disease Therapeutics - Recent Pipeline Updates, H2 2014 48
Fatty Liver Disease - Dormant Projects, H2 2014 50